HotSpot Therapeutics Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
65
- Latest Deal Type
-
2ndary - Private
- Investors
-
17
HotSpot Therapeutics General Information
Description
Developer of a therapeutic platform designed for allosteric drug discovery. The company's platform helps to identify hotspots and locate pathway treatments for cancer, metabolic, and rare diseases as well as leverages a database of hotspot structures, harnessing the power of data science in its multidisciplinary approach to drug discovery, enabling patients to get a conventional treatment against various diseases.
Contact Information
Website
www.hotspotthera.comCorporate Office
- One Design Center Place
- Suite 19-600
- Boston, MA 02210
- United States
Corporate Office
- One Design Center Place
- Suite 19-600
- Boston, MA 02210
- United States
HotSpot Therapeutics Timeline
HotSpot Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Secondary Transaction - Private | 01-Nov-2023 | Completed | Clinical Trials - Phase 1 | |||
| 4. Later Stage VC (Series C) | 16-Nov-2021 | Completed | Clinical Trials - Phase 1 | |||
| 3. Early Stage VC (Series B) | 21-May-2020 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series A) | 17-Jul-2018 | $40M | $45M | Completed | Pre-Clinical Trials | |
| 1. Seed Round | 23-Feb-2017 | $5M | $5M | Completed | Pre-Clinical Trials |
HotSpot Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | 10,000,000 | $0.000100 | 6% | $2 | $2 | 1x | $2 | 10.8% |
| Seed | 5,000,000 | $0.000100 | 6% | $1 | $1 | 1x | $1 | 5.4% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
HotSpot Therapeutics Comparisons
Industry
Financing
Details
HotSpot Therapeutics Competitors (45)
One of HotSpot Therapeutics’s 45 competitors is ROME Therapeutics, a Venture Capital-Backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ROME Therapeutics | Venture Capital-Backed | Boston, MA | ||||
| Centrose | Venture Capital-Backed | Middleton, WI | ||||
| Allorion Therapeutics | Venture Capital-Backed | Natick, MA | ||||
| Antabio | Venture Capital-Backed | Labege, France | ||||
| NexImmune | Formerly VC-backed | Gaithersburg, MD |
HotSpot Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
HotSpot Therapeutics Patents
HotSpot Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240150321-A1 | Pyrazolylsulfonamide compounds and their use in therapy | Pending | 26-Aug-2022 | ||
| US-20240150365-A1 | Pyridinylsulfonamide compounds and their use in therapy | Pending | 26-Aug-2022 | ||
| AU-2023329399-A1 | Pyrazolylsulfonamide compounds and their use in therapy | Pending | 26-Aug-2022 | ||
| AU-2023305605-A1 | Solid forms of a triazine derivative as cbl-b modulator | Pending | 12-Jul-2022 | ||
| AU-2023306375-A1 | Cbl-b inhibitors and anti-pd1/anti-pd-l1 for use in the treatment of cancer | Pending | 12-Jul-2022 | A61K31/4545 |
HotSpot Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
HotSpot Therapeutics Investors (17)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Aberdeen | Asset Manager | Minority | ||
| CaaS Capital Management | Hedge Fund | Minority | ||
| Monashee Investment Management | Hedge Fund | Minority | ||
| Nan Fung Life Sciences | Venture Capital | Minority | ||
| Pavilion Capital | PE/Buyout | Minority |
HotSpot Therapeutics Acquisitions (1)
HotSpot Therapeutics’s most recent deal was a Merger/Acquisition with Macroceutics. The deal was made on 23-Aug-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Macroceutics | 23-Aug-2019 | Merger/Acquisition | Biotechnology |
HotSpot Therapeutics FAQs
-
When was HotSpot Therapeutics founded?
HotSpot Therapeutics was founded in 2017.
-
Where is HotSpot Therapeutics headquartered?
HotSpot Therapeutics is headquartered in Boston, MA.
-
What is the size of HotSpot Therapeutics?
HotSpot Therapeutics has 65 total employees.
-
What industry is HotSpot Therapeutics in?
HotSpot Therapeutics’s primary industry is Drug Discovery.
-
Is HotSpot Therapeutics a private or public company?
HotSpot Therapeutics is a Private company.
-
What is HotSpot Therapeutics’s current revenue?
The current revenue for HotSpot Therapeutics is .
-
How much funding has HotSpot Therapeutics raised over time?
HotSpot Therapeutics has raised $210M.
-
Who are HotSpot Therapeutics’s investors?
Aberdeen, CaaS Capital Management, Monashee Investment Management, Nan Fung Life Sciences, and Pavilion Capital are 5 of 17 investors who have invested in HotSpot Therapeutics.
-
Who are HotSpot Therapeutics’s competitors?
ROME Therapeutics, Centrose, Allorion Therapeutics, Antabio, and NexImmune are some of the 45 competitors of HotSpot Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
